/ EN
HOME > NEWS&EVENTS

Press Releases

JHL BIOTECH AND ASLAN PHARMACEUTICALS TO PARTNER ON MANUFACTURING SERVICES FOR ASLAN004

15 Nov 2016

JHL BIOTECH AND ASLAN PHARMACEUTICALS
TO PARTNER ON MANUFACTURING SERVICES FOR ASLAN004

 Singapore and Hsinchu, Taiwan, 14 November 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, and JHL Biotech, Asia’s premiere provider of bespoke biologics contract manufacturing services, today announced a manufacturing services partnership under which JHL will provide process development services to ASLAN for the continued development of its ASLAN004 programme.

Under the partnership, ASLAN will work with JHL to perform process development and manufacturing of ASLAN004, a fully human monoclonal antibody that blocks the signalling of the IL-4 and IL-13 receptors.  The agreement will see ASLAN’s team work closely with JHL on analytics and process development for the manufacture of ASLAN004 for clinical trials. Development and manufacturing of ASLAN004 will commence in 2016 and will be undertaken at JHL Biotech’s GMP-certified facility in Zhubei, Taiwan.

Mark McHale, Chief Operating Officer, ASLAN Pharmaceuticals, said: “ASLAN is pleased to be working with a high quality partner like JHL, whose capabilities in process development and manufacturing will enable us to accelerate the development of our unique and proprietary biologics pipeline. Working with JHL enables ASLAN to broaden our strategic partnerships with key partners in the region as we remain focused on developing novel therapies to address Asia prevalent cancers.”

“We are excited to announce our CMC partnership with ASLAN. ASLAN is a world-class pharmaceutical company dedicated to making innovative therapies that cure Asia-specific diseases. JHL exists to make world-class medicines affordable to all, with a focus on broadening access to life-saving therapies in Asia. As such, this CMC partnership is a perfect match of ASLAN’s research and JHL’s development capabilities. We believe our collaboration on ASLAN004 will accelerate testing of this potential life-saving therapy, and we look forward to working with a team we admire and respect,” said Racho Jordanov, Chief Executive Officer of JHL Biotech. 

 

Media contacts

ASLAN Pharmaceuticals

Emma Thompson / Stephanie Tan

Spurwing Communications

Tel: +65 9171 2862

Email: ASLAN@spurwingcomms.com

JHL Biotech, Inc.

Max Chan

Chief Financial Officer

Tel: +886-(0)3-658-3899

Email: mchan@jhlbiotech.com

 

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company’s proprietary pipeline of 5 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002 (partnered with BMS), which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com

 

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase development. JHL’s facility in Wuhan, China executes commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract work on behalf of select clients. For more information, please visit www.jhlbiotech.com